ArticleClinical Medicine Insights. Oncology2026
Cost-Effectiveness of Tarlatamab in the Second-Line Treatment of Refractory Small Cell Lung Cancer From a US Perspective.
Hanrui Zheng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.